why epruma?

14
EPRUMA – Part of Responsible Use Declan O’ Brien on behalf of EPRUMA TAIEX, Istanbul, April 19th, 2011

Upload: deirdre-breslin

Post on 31-Dec-2015

16 views

Category:

Documents


1 download

DESCRIPTION

EPRUMA – Part of Responsible Use Declan O’ Brien on behalf of EPRUMA TAIEX, Istanbul, April 19th, 2011. Why EPRUMA?. The motivation behind launching EPRUMA was to build stakeholder agreement on what constitutes “Responsible Use” of veterinary medicines - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Why EPRUMA?

EPRUMA – Part of Responsible Use

Declan O’ Brien on behalf of EPRUMATAIEX, Istanbul, April 19th, 2011

Page 2: Why EPRUMA?

Why EPRUMA?

The motivation behind launching EPRUMA was to build stakeholder agreement on what constitutes “Responsible Use” of veterinary medicines

We have very good agreement & collaboration across European stakeholders:

COPA-COGECA (farmers & co-operatives), EISA (European Initiative for Sustainable Development in Agriculture), FECAVA (small animal vets), FEFAC (feed manufacturers), FESASS (animal-health farmer organisations), FVE (veterinary surgeons) & IFAH-Europe (animal health industry), PGEU (pharmacists)

All pre-farm gate stakeholders support EPRUMA We actively welcome new members

Page 3: Why EPRUMA?

EPRUMA partners:

Page 4: Why EPRUMA?

Objectives of EPRUMA

Promote animal health & welfare as well as human health through the “Responsible Use” of veterinary medicines

an essential component of public health Develop “best practice” frameworks concerning the use of

veterinary medicines Communicate with & involve all parties concerned with

the “Responsible Use” of veterinary medicines

Page 5: Why EPRUMA?

“Responsible Use” of Veterinary Medicines Bio-security: preventative measures aimed at keeping

diseases out of groups of animals or to limit the spread of disease within an animal population

Good housing Appropriate nutrition Regular monitoring of health and welfare Herd health plans: tailored to record specific actions for

individual farms Vaccination Diagnosis and treatment under veterinary care Use medicines according to instructions

Page 6: Why EPRUMA?

Policy Context

Medicated Feed legislation being reviewed Veterinary Directive being reviewed Commission ‘Staff Working Paper’ consultation CVMP consultation Heads of Medicines Agencies consultation EU/US dialogue Innovation being promoted – Europe 2020

Page 7: Why EPRUMA?

Communication Activities

Website launched during Vet Week in June, 2010 Antimicrobial framework translated into Czech, Dutch,

English, French, German, Hungarian, Italian, Polish, Romanian, Turkish & Spanish!

EPRUMA present at relevant conferences – e.g. Vet Week, Congress of European Farmers

Plan to present to veterinary students across Universities Plan to include in Continuous Professional Development

courses for practicing veterinarians Leaflet & ‘roll up’ developed & Poster being developed

Page 8: Why EPRUMA?
Page 9: Why EPRUMA?

Vet Week, June, 2010

Page 10: Why EPRUMA?

Additional Antimicrobial Initiatives

EPRUMA welcomes the EMA initiative on collecting volume information across the EU

Important information that has not been available to date

Ongoing reports from EFSA provide additional valuable information

Need to also present Clinical breakpoint data EU/US Dialogue ongoing Animal Health Law & “One Health”

Page 11: Why EPRUMA?

Implementation in the Field

Met with Commissioner Dalli in September, 2010 Need to communicate Provide information to those who make the decisions

especially veterinarians Continuous Professional Development as route

Page 12: Why EPRUMA?

Industry Recommendations - 1

• We should use all existing & new classes strategically – possibly in rotation & guided by diagnostics - to minimise resistance development to all classes

• We can protect the efficacy of existing & new antibiotics via ongoing diagnostics – use to inform future antimicrobial choices

• We promote the idea of significantly restricting the ‘cascade’ as a means of combating resistance – cascade by ‘exceptional exception’ but critical to have the cascade

Page 13: Why EPRUMA?

Industry Recommendations - 2

• We propose extended data protection for new molecules to ensure innovation continues

• With a combination of diagnostics, restrictions on off label use, appropriate use of new molecules & classes coupled with extended data protection, concerns of most stakeholders have been addressed

Page 14: Why EPRUMA?

Conclusions EPRUMA has established very constructive collaboration

across stakeholders EPRUMA has been very active in promoting “Responsible

Use” Our activities complement European policy & legislation We need support to communicate “Responsible Use” and to

really make a difference on the ground Strategic use of all classes supported by diagnostics can

protect long term efficacy Restrict use of ‘cascade’ but critical to have it Stimulate innovation EPRUMA is a critical part of an overall policy to protect the

long term efficacy of antimicrobials